Flot.bio x Philip Hemme – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Flot.bio x Philip Hemme

Flot.bio

Sciences

Fréquence : 1 épisode/21j. Total Éps: 63

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 15/10/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

http://eepurl.com/h_fnmH
93 partages
https://www.paypal.me/PhilipHemme
79 partages
https://flot.bio/most-valuable-biotech-companies-europe-2025/
14 partages

https://www.linkedin.com/company/flot-bio/
91 partages
https://www.linkedin.com/company/flot-bio/-
9 partages
https://www.linkedin.com/in/christoph-lengauer-75b7961b/

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 48%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Épisode 63

mardi 13 octobre 2026 • Durée 31:10

Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners before joining Angelini Ventures in 2025. The corporate venture fund now manages close to €500M, and its first exit, Noctrix Health, sold to ResMed for $340M in June.We talked about Forbion, Jeito and Sofinnova’s mega-funds, why Europe still needs more institutional money for biotech, and why “spray and pray” doesn’t work at the Series A and B levels of investing.We also covered the “red hot” rare-disease segment, and why her biotech hero is Nobel laureate Sir Gregory Winter.

---This episode is brought to you by Avance Life Sciences, where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance---

⭐️ ABOUT THE SPEAKER

Since starting her Managing Director role at Angelini Ventures in 2025, Regina has served on the boards of companies including Adcytherix and Nuclidium. She was previously Managing Partner at Wellington Partners, where she managed 25+ investments, including Themis and Rigontec, both acquired by MSD.She was also a founding investor in Bicycle Therapeutics and F-star, and earlier worked at Atlas Venture, Apax and McKinsey.

🔗 LINKS MENTIONED

Regina Hodits LinkedIn profile — https://www.linkedin.com/in/regina-hodits-270a7481/
Angelini Ventures — angeliniventures.com
EIB and Angelini Ventures, €150M agreement — eib.org
Angelini Ventures invests in Epicrispr's $90M Series C — angeliniventures.com
ResMed acquires Noctrix Health, $340M — fiercebiotech.com
RougeTx launches with $58M Series A — rougetx.com
Forbion raises €2.3B across two funds — forbion.com
Jeito II, record €1B fundraise — jeito.life
Angelini Pharma to acquire Catalyst Pharmaceuticals — angelinipharma.com
Christoph Lengauer, Curie.Bio, Flot.Bio E57 — flot.bio
Otello Stampacchia, Omega Funds, Flot.Bio E18 — flot.bio
Gilead completes acquisition of Tubulis — gilead.com
Adcytherix raises €105M Series A — adcytherix.com
Pascal Touchon, Jeito, Flot.Bio E49 — flot.bio
European Life Sciences Coalition launch — forbion.com
Sander Slootweg, Forbion, Flot.Bio E56 — flot.bio
Dominik Schumacher, Tubulis, Flot.Bio E19 — flot.bio
Sir Gregory Winter, Nobel biography — nobelprize.org

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/regina-hodits-angelini-ventures-biotech/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.Bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

[00:00:00] Intro
[00:02:33] From Wellington Partners to Angelini Ventures
[00:03:29] Freedom In A €300M Evergreen Fund
[00:06:31] CNS, Rare Disease and Oncology: Key Strengths
[00:09:57] Family-Owned Angelini Pharma: Serving Two Masters
[00:15:41] Fund Returns: It’s Not Just Spray And Pray
[00:18:36] Platforms vs Assets: Bicycle, Tubulis and Adcytherix
[00:21:51] Forbion and Jeito’s Mega-Funds: Democratizing Europe's Biotech Capital
[00:25:15] Regina Hodits Offers Lessons for Venture Investors
[00:28:06] Quick-Fire Questions

Lire plusRéduire

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Épisode 62

lundi 28 septembre 2026 • Durée 57:29

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a second.We also talked about France’s biotech giants, the landscape of long-acting injectables, and why Christophe was once in charge of a remote fishing lodge in Canada.---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN---

⭐️ ABOUT THE SPEAKER

Before his time as CEO of MedinCell, Christophe was lead investor in Nanobiotix and served in roles at the Boston Consulting Group, and Matignon Investissement & Gestion.He also spent 15 years in North America, and he holds an engineering degree from École des Mines de Paris, a Master’s degree from the University of Minnesota, and an MBA from the University of Calgary.

🔗 LINKS MENTIONED

Christophe Douat LinkedIn profile — https://www.linkedin.com/in/christophe-douat-16268a/
MedinCell — medincell.com
Teva — tevapharm.com
Uzedy FDA approval, April 2023 — https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-/
MedinCell investor presentation, Sept 2026 — https://www.medincell.com/wp-content/uploads/2026/09/Investors-Sept2026.pdf
Pascal Touchon, Flot.bio E49 — https://flot.bio/episode/pascal-touchon-jeito/
Fredrik Tiberg, Flot.Bio E51 (Camurus) — https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/

Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61

Épisode 61

lundi 6 juillet 2026 • Durée 01:14:40

Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress of AtaiBeckley, and why he thinks ‘going home and sleeping’ beats an all-nighter every time.

---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN---

⭐️ ABOUT THE SPEAKER

Christian is the founder of Apeiron Investment Group, which manages around $7 billion across psychedelics, longevity, consumer biotech, crypto and media. He also co-founded big companies including AtaiBeckley and the Enhanced Games.Christian studied business in Germany at the University of Bayreuth but dropped out to co-found Ribopharma, which merged with Alnylam Pharmaceuticals in 2003.

🔗 LINKS MENTIONED

Christian Angermayer LinkedIn profile — https://www.linkedin.com/in/christian-angermayer/
Enhanced Games — https://www.enhanced.com/
Enhanced Games inaugural event press release — https://investors.enhanced.com/inaugural-enhanced-games-deliver-a-world-record-and-21-personal-bests-showcasing-that-living-enhanced-works/
David Nutt LinkedIn profile — https://www.linkedin.com/in/professor-david-nutt-82498025/
AtaiBeckley pipeline — https://www.ataibeckley.com/our-work/pipeline
BBC weight loss drugs comparison — https://www.bbc.com/news/articles/c981044pgvyo

ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60

Épisode 60

lundi 8 juin 2026 • Durée 47:24

After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025.

In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology space, including highlights from ASCO 2026, ADCs, in vivo CAR-T & checkpoint inhibitors.

He reveals some of the most shocking lessons he learned from his time at Imcheck.

---Learn more about Kadans’ Oncology Clusters, where oncology biotechs grow from start-up to global player: https://bit.ly/kadans-oncology---

⭐️ ABOUT THE SPEAKERPierre has 30 years of experience in the biopharmaceutical industry, including 9 years at ImCheck and more than 3 years as EVP, Chief Strategy Officer at Theravectys. Prior to this, he also spent 10 years in senior roles in Sanofi and Baxter Healthcare.

🔗 LINKS MENTIONED

Kadans Oncology Summit — https://www.kadansoncologysummit.com/
ImCheck Therapeutics — https://www.imchecktherapeutics.com/
ImCheck ASCO data (2025) — https://www.imchecktherapeutics.com/all-press-release/news/imcheck-reports-high-remission-rates-in-aml-patients-with-ict01-combination-therapy-at-asco-2025/
ImCheck acquisition by Ipsen (2025) — https://www.ipsen.com/press-release/ipsen-to-acquire-imcheck-therapeutics-expanding-its-leadership-in-oncology-strengthening-its-pipeline-3170788/
Pancreatic cancer ASCO data (2026) — https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer

CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]

Épisode 59

lundi 1 juin 2026 • Durée 01:01:30

Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise investments.Jean‑François tells us how the exit unfolded, as well as the importance of biosafety and CMC as pharma and biotech outsource heavily and cell and gene therapies mature. We also cover how animal testing is disappearing from CMC and how France must nurture its biotech ecosystem.

---For transparency, this episode has been sponsored by PathoQuest.---

⭐️ ABOUT THE SPEAKER

Jean-François has more than 20 years of pharma leadership under his belt. Before his ten years at PathoQuest, he was a Senior Vice-President in charge of Ipsen’s GI-oncology and endocrinology franchise.He has an engineering degree and a master’s degree in Foreign Trade.

🔗 LINKS MENTIONED

CRL acquires PathoQuest (2026) — https://pathoquest.com/press-release-pathoquest-to-join-charles-river-laboratories-2/
Werner Lanthaler | Biopharma AI, CDMO, Antibody Optimization | E48 — https://flot.bio/episode/werner-lanthaler-biopharma-ai/
Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership (2018) — https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-and-pathoquest-expand-strategic
Charles River and PathoQuest validate viral safety assay (2023) — https://ir.criver.com/news-releases/news-release-details/charles-river-and-pathoquest-announce-publication-head-head
Philipp Baaske, NanoTemper | Bootstrapping in Biotech | E29 — https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/

Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58

Épisode 58

lundi 25 mai 2026 • Durée 58:35

When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping $5 billion. We talk about the bureaucracy of Big Pharma, rare diseases, and why a biotech M&A supercycle isn’t as likely as you'd think.

---Discover the best biotech companies in 🇪🇺 with the FlotBio Map. https://bit.ly/4nXmKjN---

⭐️ ABOUT THE SPEAKER

Prior to his time at Incyte, Hervé led the oncology business unit at Novartis and had leading roles at Aventis (now Sanofi). He is currently on the boards of companies including Incyte, Pierre Fabre, & Bicycle Therapeutics.

🔗 LINKS MENTIONED

Pascal Touchon | Cell Therapy, Jeito, Kymriah | E49 —https://flot.bio/episode/pascal-touchon-jeito/
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50— https://flot.bio/personalized-cancer-vaccine-oncolytic-viruses/
Penn and Novartis CAR-T alliance (2012) — https://penntoday.upenn.edu/news/university-pennsylvania-and-novartis-form-alliance-expand-use-personalized-t-cell-therapy-cance
Incyte and Novartis deal (2009) —https://investor.incyte.com/news-releases/news-release-details/incyte-announces-major-collaboration-and-license-agreement-two
Hoppenot steps down as Incyte CEO (2025) — https://investor.incyte.com/news-releases/news-release-details/incyte-announces-change-its-board-directors

Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57

Épisode 57

lundi 11 mai 2026 • Durée 01:19:16

We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio candidate Forward Therapeutics in Phase I.We also talk about major bottom-up successes including argenx, Ascendis and Genmab, and how life sciences investing differs from tech investing.Christoph also explains his ‘rebel’ mindset and why founders shouldn’t accept the status quo.

---This episode is brought to you by Avance, where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance---

⭐️ ABOUT THE SPEAKER

Christoph co-founded of Curie.Bio in 2022, after serving as Partner at Third Rock Ventures for 6 years. He also had leading roles at Blueprint Medicines for ten years, and at MOMA Therapeutics for one year.He has also been an Adjunct Associate Professor at Johns Hopkins University for more than 20 years, with past roles at Celsius Therapeutics, Sanofi, and Novartis. 🔗 LINKS MENTIONED

Curie.Bio — https://curie.bio/
Christoph Lengauer — https://www.linkedin.com/in/christoph-lengauer-75b7961b/
Sanofi to acquire Blueprint Medicines — https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541
Forward Therapeutics Announces $50 Million Series A Financing —https://forward-tx.com/press-release/forward-therapeutics-announces-50-million-series-a-financing/
Gilead to Acquire Tubulis — https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline

Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56

Épisode 56

lundi 13 avril 2026 • Durée 01:06:42

Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences investments in Europe via the Life Sciences VC Coalition. We chat about building European biotech champions like Argenx, the thriving Chinese biotech space, and why life should be fun, not only dealflow.

---

This episode is brought to you by GeneNovate Investors Day, an invite-only event for scientists, startups, investors, and industry leaders working at the forefront of cell and gene therapies. Learn more: https://bit.ly/flot-genenovate or reach out to [nadja.pahl@bih-charite.de](mailto:nadja.pahl@bih-charite.de)

---

⭐️ ABOUT THE SPEAKER

Sander co-founded Forbion in 2006. Prior to co-founding Forbion, Sander co-founded ABN AMRO Capital/Life Sciences in 2000. Sander serves on the boards of NorthSea Therapeutics & Azafaros, with previous board roles at NewAmsterdam Pharma, Replimune & uniQure.

🔗 LINKS MENTIONED

Forbion website — https://forbion.com/

Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]

Épisode 55

mercredi 8 avril 2026 • Durée 01:02:50

Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines.

We discuss how Immunethep could challenge Pfizer’s $7bn+ Prevnar, and how one pharma company got on board after a representative said he doesn’t believe in vaccines!

---

For transparency, this episode has been sponsored by Immunethep. Learn more at https://bit.ly/flot-immunethep

---

⭐️ ABOUT THE SPEAKERS

Bruno is Immunethep’s co-founder and CEO, and co-founder of the startup creator Venture Catalysts. He also co-founded the tech startup Abyssal, which was acquired by marine robotics company Ocean Infinity in 2021.

Co-founder and CSO Pedro is a biomedical scientist previously serving as an Assistant Researcher at i3S. He has a PhD in Biomedical Sciences from the University of Porto and boasts over 30 peer-reviewed publications.

🔗 LINKS MENTIONED

Immunethep website — https://www.immunethep.com/
When Cancer is no longer the biggest threat: AMR’s growing shadow over oncology —

António Portela, Bial 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54

Épisode 54

lundi 30 mars 2026 • Durée 31:23

We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned.

We cover Bial’s pipeline, including treatments for epilepsy and Parkinson’s, and why Bial’s multigenerational leadership story is nowhere as dramatic as HBO’s “Succession.”

---Avance is where European biotech turns for trusted financial advice. Learn more at https://bit.ly/flot-avance.---

⭐️ ABOUT THE SPEAKER

Prior to leading Bial, António worked at Roche in the UK as a Medical Sales Representative and a Market Analyst. While he worked at Roche, he also launched a Hepatitis C drug.António holds a degree in Economics from the Faculty of Economics at the University of Porto and an Executive MBA from the Porto Business School.

🔗 LINKS MENTIONED

Bial’s website — https://www.bial.com/en
Bial 2024 financials — https://downloads.ctfassets.net/oyx9uzi3vj2y/XTmSUhXd7ggVEnpJLx0Ch/7a22a851246d910c517e064fca4b6968/Consolidated_Management_Report_BIAL_Holding_2024.pdf
Bial launches KYNMOBI in Portugal and Spain — https://bial.com/en/media/news/bial-launches-kynmobi-in-portugal-and-spain
Succession TV show — https://www.imdb.com/title/tt7660850/

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Flot.bio x Philip Hemme. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !